Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
By K. Wachtell, M. Lehto, E. Gerdts, M. Olsen, B. Hornestam, B. Dahlöf, H. Ibsen, S. Julius, S. Kjeldsen, L. Lindholm and 2 more. Journal of the American College of Cardiology, 2005
790 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/8df2939c42d06b83b6017bf13058faf109a10e4a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Gerhard Hindricks
- Gregory Y. H. Lip
- S. Laurent
- A. Goette
- Rick A. Nishimura
- Paulus Kirchhof
- Ulrich Schotten
Citations in the corpus
- ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit (2006, positive): “Angiotensin inhibition may be associated with a reduced incidence of AF in patients with HF(15) and hypertension.(16)”